Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Cabenuva is a prescription long-acting HIV-1 regimen containing cabotegravir and rilpivirine extended-release injectable suspensions. It replaces a stable antiretroviral regimen in virologically suppressed adults and adolescents age 12 and older who weigh at least 35 kg, have no history of treatment failure, and have no known or suspected resistance to either medicine.
read more about cabenuva ...Cabotegravir is an integrase strand transfer inhibitor that blocks insertion of viral DNA into human cell DNA. Rilpivirine is a non-nucleoside reverse transcriptase inhibitor that binds HIV-1 reverse transcriptase and disrupts viral DNA synthesis. Together, these long-acting antiretroviral medicines maintain suppression of HIV-1 replication between scheduled injection visits.
Cabenuva is used in adults and adolescents age 12 and older who weigh at least 35 kg and already have HIV-1 RNA below 50 copies per mL on a stable regimen. Eligible patients have no history of treatment failure and no known or suspected resistance to cabotegravir or rilpivirine.
Cabenuva is given by a healthcare professional as two separate gluteal intramuscular injections during the same visit. Treatment can follow a monthly or every-two-month schedule. An oral lead-in with cabotegravir 30 mg and rilpivirine 25 mg daily for at least 28 days is optional before injections. Direct initiation with injections is also permitted.
Serious risks include hypersensitivity reactions, post-injection reactions, liver toxicity, depressive disorders, and loss of virologic response with drug interactions or missed doses. Long-acting drug concentrations can remain in the body for 12 months or longer after the last injections. Scheduled visits and timely replacement antiretroviral treatment after discontinuation reduce the risk of resistance.
Cabenuva contains long-acting injectable cabotegravir and rilpivirine.
Current labeling includes virologically suppressed adults and adolescents age 12 and older who weigh at least 35 kg and meet resistance and treatment-history criteria.
Cabenuva can be given once monthly or every two months after the appropriate initiation schedule.
No. An oral lead-in is optional. Eligible patients can proceed directly to the injection regimen.
CABENUVA (cabotegravir and rilpivirine) Prescribing Information. https://gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Cabenuva/pdf/CABENUVA-PI-PIL-IFU2-IFU3.PDF. Date Accessed September 18, 2026.
Cabotegravir and Rilpivirine Injection. MedlinePlus. https://medlineplus.gov/druginfo/meds/a621009.html. Date Accessed September 18, 2026.
DailyMed - CABENUVA (cabotegravir and rilpivirine) kit. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1698baf3-f895-4c42-a1b1-e9ee3f20da36. Date Accessed September 18, 2026.
FDA-Approved HIV Medicines. HIVinfo. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/fda-approved-hiv-medicines. Date Accessed September 18, 2026.
Long-Acting HIV Medicine. HIVinfo. https://hivinfo.nih.gov/understanding-hiv/fact-sheets/long-acting-hiv-medicine. Date Accessed September 18, 2026.